



truscreen
a world without
cervical cancer

12 February 2024

NZX

TruScreen to launch a pro-rata renounceable rights issue

TruScreen Group Limited (NZX/ASX:TRU) (**TruScreen** or **TRU**) is pleased to announce its intention to launch a one (1) for three (3) pro-rata renounceable rights issue to raise up to circa NZD\$2.8 million ("**Rights Offer**").

An Offer Document will be issued by TruScreen and released to the market in due course. Shareholders should read the Offer document in full before deciding what actions to take with their rights. Details of the Rights Offer are as follows:

Rights Offer size and structure	~NZD\$2.8 million pro rata renounceable rights offer to Eligible Shareholders (defined below) at a ratio of 1 for 3 (Rights Offer). 140,008,446 New fully paid ordinary Shares in TruScreen (New Shares) will be issued under the Rights Offer.
Rights Offer price	NZD\$0.02/AUD\$0.0187 per New Share (Issue Price)
No Rights trading	Rights will not be quoted on the NZX Main Board or the ASX. Holders of Rights shall be entitled to sell their Rights privately off-market.
Eligibility	Only TruScreen shareholders with registered addresses in New Zealand or Australia on the Record Date will be entitled to participate in the Rights Offer (Eligible Shareholders).
Oversubscriptions	Eligible Shareholders who elect to take up all of their Rights in full will have an opportunity to apply for additional shares (Shortfall Shares).
Ordinary Shares	The New Shares to be issued under the Rights Offer will rank equally in all respects with the existing ordinary shares on issue in TRU.

The key dates for the Rights Offer are as follows:

Announcement of the Offer	12 February 2024
Record Date for determining Rights	5pm (NZDT)/3pm (AEDT) 20 February 2024
Opening Date for the Offer	21 February 2024
Dispatch of Offer Documents and Entitlement and Acceptance Forms	On or before 27 February 2024
Closing Date for the Offer	5pm (NZDT)/3pm (AEDT) 13 March 2024
Announcement of results of the Offer	18 March 2024
Allotment of New Shares, despatch of holder statements and commencement of trading of New Shares	20 March 2024



The above dates are subject to change at the discretion of TRU, subject to compliance with NZX and ASX Listing Rules requirements. TRU reserves the right to withdraw the Rights Offer at any time prior to the issue of New Shares under the Rights Offer at its absolute discretion.

A copy of the Corporate Action Notice and the Cleansing Notice accompany this announcement.

Ends

Tony Ho
Chairman
Tel: +61 41 734 5839
Email: tonyho@truscreen.com

For investor relations queries please visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"[®].

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*